Establishment registration and drug listing data is submitted by drug manufacturers and own label drug distributors through electronic means using Structured Product Labeling format (SPL).
Similar Posts
Biocon Sdn. – 8/30/2022
Biocon Sdn. – 8/30/2022. Country: Malaysia. Record Type: 483Citalopram (marketed as Celexa) Information
Citalopram (marketed as Celexa) InformationPromotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers
The guidance addresses questions that manufacturers, packers, distributors, and their representatives (firms) may have when developing FDA-regulated promotional labeling and advertisements for prescription reference products, biosimilar products, and interchangeable biosimilar products.FDA Drug Competition Action Plan | Improving the efficiency of the generic drug development, review, and approval process
By clarifying FDA’s regulatory expectations for new entrants and experienced drug developers alike, FDA is supporting prospective generic drug developers and improving the overall quality of ANDAs submitted to the Agency for approval.Zydus Lifesciences Limited – 9/5/2025
Zydus Lifesciences Limited – 9/5/2025. Country: India. Record Type: 483CDER Conversations
Interviews with experts from FDA’s Center for Drug Evaluation and Research (CDER) on priorities, projects, and initiatives.